Q702 for the Treatment of Patients With Hematologic Malignancies

Inclusion Criteria: * PRE-REGISTRATION: Age ≥ 18 years * PRE-REGISTRATION: Not eligible for or have failed therapies with established benefits, at the discretion of the treating physician * PRE-REGISTRATION: Patients must meet one of the following criteria: * Relapsed/refractory patients with Erdheim-Chester disease, Langerhans histiocytosis, histiocytic sarcoma, or other malignant histiocytosis without activating alterations in v-Raf murine sarcoma viral oncogene homolog B (BRAF) or Mitogen-activated protein kinase kinase (MAP2K) oncogenes who have progressed after first line of therapy. * Note: Relapsed is defined as a relapse that occurred after having a response to the last therapy at any point during the treatment. Refractory is no response (stable disease or progressive disease while on therapy) to a given treatment at least after 1 month of being on the given treatment. * Newly diagnosed patients with Rosai-Dorfman disease without activating alterations in MAP2K oncogenes. * Relapsed/refractory patients with Rosai-Dorfman disease and an activating mitogen-activated protein kinase (MAPK) pathway alteration who have failed prior treatment with cobimetinib. * Relapsed/refractory patients with Erdheim-Chester disease or Langerhans histiocytosis who have received vemurafenib for BRAF V600E mutated disease or cobimetinib for disease with activating MAP2K alterations. * Patients with Erdheim-Chester disease, Rosai-Dorfman disease, Langerhans histiocytosis, hi…